Loading
A phase 1/2 trial of RO7771950, Pertuzumab in her2-positive breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05593094 by Hoffmann-La Roche, with 210 participants planned, started 2020-09-03 and due to reach its primary completion in 2027-08-31. Interventions recorded: ZN-A-1041, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c. Conditions listed: Advanced Solid Tumors, HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares RO7771950, UCSF Helen Diller Family Comprehensive Cancer Center, Roche / Genentech, HER2-positive breast cancer.
Shares Pertuzumab, UCSF Helen Diller Family Comprehensive Cancer Center.
Shares Pertuzumab, HER2-positive breast cancer.
Shares Pertuzumab, UCSF Helen Diller Family Comprehensive Cancer Center.
Shares Pertuzumab, HER2-positive breast cancer.
Shares Pertuzumab, UCSF Helen Diller Family Comprehensive Cancer Center.
Shares Pertuzumab, UCSF Helen Diller Family Comprehensive Cancer Center, HER2-positive breast cancer.
Shares Pertuzumab, HER2-positive breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/